stage IV squamous cell carcinoma of the oropharynx
Showing 26 - 50 of >10,000
Oral Squamous Cell Carcinoma Trial in Beijing (Toripalimab)
Not yet recruiting
- Oral Squamous Cell Carcinoma
-
Beijing, ChinaPeking Union Medical College Hospital, Chinese Academy of Medica
Apr 5, 2023
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally
Recruiting
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- +5 more
- Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101
- Pembrolizumab
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 4, 2023
Squamous Cell Carcinoma of the Oropharynx Trial in Paris (Tumor Biopsy)
Not yet recruiting
- Squamous Cell Carcinoma of the Oropharynx
- Tumor Biopsy
-
Paris, France
- +2 more
Sep 25, 2023
Squamous Cell Carcinoma of the Oropharynx, HPV Positive Oropharyngeal Squamous Cell Carcinoma Trial in Carmel, Indianapolis (44
Recruiting
- Squamous Cell Carcinoma of the Oropharynx
- HPV Positive Oropharyngeal Squamous Cell Carcinoma
- 44 doses of radiation
- 54 doses of radiation
-
Carmel, Indiana
- +1 more
Oct 5, 2022
Head and Neck Carcinoma of Unknown Primary, Head and Neck Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell
Active, not recruiting
- Head and Neck Carcinoma of Unknown Primary
- +19 more
- Berzosertib
- +3 more
-
Duarte, California
- +18 more
Aug 24, 2022
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma,
Not yet recruiting
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- +10 more
- Carboplatin
- +9 more
- (no location specified)
Jan 31, 2023
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma,
Recruiting
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- +24 more
- Carboplatin
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
May 18, 2022
Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Stage IV Cutaneous Squamous Cell
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- +2 more
- Panitumumab
- +4 more
-
Nashville, TennesseeVanderbilt University/Ingram Cancer Center
Feb 16, 2023
Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Oral Cavity
Active, not recruiting
- Squamous Cell Carcinoma of the Oropharynx
- +7 more
-
Tampa, Florida
- +2 more
Dec 30, 2022
Neoadjuvent, PD-1 Inhibitor, Chemo Trial in Xi'an (Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin)
Recruiting
- Neoadjuvent
- +3 more
- Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin
-
Xi'an, Shaanxi, China
- +2 more
Aug 17, 2023
Head Neck Cancer, Metastatic Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma Trial in Winston-Salem (Pembrolizumab,
Recruiting
- Head Neck Cancer
- +5 more
- Pembrolizumab
- +2 more
-
Winston-Salem, North CarolinaWake Forest Baptist Health Sciences
Aug 8, 2022
Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell
Recruiting
- Head and Neck Squamous Cell Carcinoma
- +23 more
- Biospecimen Collection
- +2 more
-
Los Angeles, California
- +1 more
Jul 7, 2022
ESCC Trial (Tislelizumab combined with chemoradiotherapy)
Not yet recruiting
- ESCC
- Tislelizumab combined with chemoradiotherapy
- (no location specified)
Sep 18, 2022
Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma Trial
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- +14 more
- Biospecimen Collection
- +9 more
- (no location specified)
Oct 10, 2023
Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma, Unknown Primary Trial in Liverpool (Versius Surgical System)
Not yet recruiting
- Squamous Cell Carcinoma of the Oropharynx
- Squamous Cell Carcinoma, Unknown Primary
- Versius Surgical System
-
Liverpool, United KingdomLiverpool Head and Neck Centre, ENT Department Liverpool Univers
Oct 27, 2023
Clinical Stage III Human Papillomavirus (HPV)-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV
Recruiting
- Clinical Stage III Human Papillomavirus (HPV)-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- +28 more
- Cisplatin
- +3 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Dec 16, 2022
HPV Related Oropharyngeal Squamous Cell Carcinoma Trial in Saint Louis (drug, radiation, procedure, other)
Active, not recruiting
- HPV Related Oropharyngeal Squamous Cell Carcinoma
- Cisplatin
- +8 more
-
Saint Louis, MissouriWashington University School of Medicine
Mar 23, 2022
Cancer, Melanoma Stage III, Melanoma Stage IV Trial (KB707)
Not yet recruiting
- Cancer
- +6 more
- KB707
- (no location specified)
Jul 24, 2023
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive)
Recruiting
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- +10 more
- Intensity-Modulated Radiation Therapy
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Nov 8, 2022
Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IVA
Withdrawn
- Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity
- +6 more
- hypofractionated radiation therapy
- +3 more
-
New Brunswick, New Jersey
- +1 more
Sep 27, 2022
Carcinoma, Squamous Cell of Head and Neck, Oropharynx Squamous Cell Carcinoma Trial in Atlanta, Portland, Pittsburgh (Nivolumab
Active, not recruiting
- Carcinoma, Squamous Cell of Head and Neck
- Oropharynx Squamous Cell Carcinoma
- Nivolumab Injection
- Radiotherapy (RT)
-
Atlanta, Georgia
- +2 more
Mar 24, 2022
Advanced Clear Cell Renal Cell Carcinoma, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant, Infiltrating Bladder
Active, not recruiting
- Advanced Clear Cell Renal Cell Carcinoma
- +35 more
- Cabozantinib S-malate
- +2 more
-
Duarte, California
- +7 more
Jan 3, 2023
Head and Neck Tumors Trial (TransCon TLR7/8 Agonist, Pembrolizumab, TransCon IL-2 ß/?)
Not yet recruiting
- Head and Neck Neoplasms
- TransCon TLR7/8 Agonist
- +2 more
- (no location specified)
Aug 4, 2023